- Home
- ACAD vs SNDR Comparison
ACAD vs SNDR Comparison
Compare ACAD & SNDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- SNDR
- Stock Information
- Founded
- ACAD 1993
- SNDR 1935
- Country
- ACAD United States
- SNDR United States
- Employees
- ACAD N/A
- SNDR N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- SNDR Trucking Freight/Courier Services
- Sector
- ACAD Health Care
- SNDR Industrials
- Exchange
- ACAD Nasdaq
- SNDR Nasdaq
- Market Cap
- ACAD 4.3B
- SNDR 4.5B
- IPO Year
- ACAD 2004
- SNDR 2017
- Fundamental
- Price
- ACAD $23.61
- SNDR $23.84
- Analyst Decision
- ACAD Buy
- SNDR Buy
- Analyst Count
- ACAD 21
- SNDR 13
- Target Price
- ACAD $29.30
- SNDR $27.54
- AVG Volume (30 Days)
- ACAD 1.9M
- SNDR 711.4K
- Earning Date
- ACAD 11-05-2025
- SNDR 11-05-2025
- Dividend Yield
- ACAD N/A
- SNDR 1.58%
- EPS Growth
- ACAD 615.00
- SNDR 5.54
- EPS
- ACAD 1.33
- SNDR 0.70
- Revenue
- ACAD $1,018,885,000.00
- SNDR $5,477,100,000.00
- Revenue This Year
- ACAD $14.01
- SNDR $10.56
- Revenue Next Year
- ACAD $11.72
- SNDR $5.64
- P/E Ratio
- ACAD $17.82
- SNDR $34.36
- Revenue Growth
- ACAD 14.41
- SNDR 2.20
- 52 Week Low
- ACAD $13.40
- SNDR $20.59
- 52 Week High
- ACAD $26.65
- SNDR $33.90
- Technical
- Relative Strength Index (RSI)
- ACAD 39.78
- SNDR 42.55
- Support Level
- ACAD $23.70
- SNDR $23.64
- Resistance Level
- ACAD $25.90
- SNDR $24.63
- Average True Range (ATR)
- ACAD 0.74
- SNDR 0.55
- MACD
- ACAD -0.33
- SNDR -0.06
- Stochastic Oscillator
- ACAD 8.16
- SNDR 12.35
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About SNDR Schneider National Inc.
Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, intermodal, and logistics services to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload; Intermodal; Logistics and other. It generates maximum revenue from the Truckload segment.